Abstract
MicroabstractBy retrospectively analyzing the clinicopathologic, immunohistochemical, molecular genetic aspect, postoperative adjuvant therapeutic regime including ICB and prognosis-related information of ALK-RCCs, we aim to explore the unique biological behavior and improve the knowledge of the neoplasm and expand upon the therapy regimen of CIT especially ICB.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call